Company Overview
Cellyan Biotechnology Co., Ltd operates as an investment holding company focused on the over-the-counter pharmaceutical business within Hong Kong and Mainland China. The firm specializes in providing OTC pharmaceutical cross-border procurement and distribution services alongside e-commerce supply chain operations, while also offering custom solutions within the healthcare sector. This entity functions within the broader Healthcare sector, specifically classified under the industry of Pharmaceutical Retailers, a classification that denotes its primary reliance on the sale and distribution of non-prescription medicines rather than drug development or manufacturing. The company's current scale is defined by a market capitalization of $7.48M and annual revenue of $16.36M, supported by a workforce of 27 employees. These valuation and revenue figures indicate that Cellyan Biotechnology is a small-cap entity with a relatively modest operational footprint compared to larger pharmaceutical distributors, suggesting a niche positioning within the cross-border trade and e-commerce supply chain segments of the Hong Kong market.
Financial Health
The company reported revenue of $16.36M over the trailing twelve months, yet it recorded a net income of $-701,880 and an EBITDA of $-534,478, revealing a significant gap between top-line generation and profitability. This substantial disparity between revenue and net income highlights a cost structure where operating expenses, including the costs associated with cross-border procurement and distribution logistics, heavily outweigh the gross profits generated from sales. Despite the reported net loss, the company maintains a free cash flow of $2.44M, which provides a degree of financial flexibility by indicating that cash inflows from operations are sufficient to cover operating cash outflows and potentially fund working capital needs. The margin profile shows a gross margin of 8.8%, an operating margin of 3.0%, and a profit margin of -4.3%, indicating that while the core product sales generate some gross profit, high operating costs are eroding those gains to result in an overall loss. On the balance sheet, the company holds $2.48M in cash against $2.27M in debt, resulting in a debt-to-equity ratio of 44.19, which suggests a leveraged position where debt levels are significant relative to equity, though absolute debt remains manageable against available liquidity. Short-term liquidity is supported by a current ratio of 2.93, indicating that the company possesses nearly three times the current assets required to meet its short-term liabilities. However, the return metrics present a challenging picture for management effectiveness, with a return on equity of -13.4% and a return on assets of -3.9%, demonstrating that the company is currently destroying value relative to both shareholder equity and total asset base.
Valuation Assessment
The P/E Ratio (TTM) is listed as N/A due to the negative net income, and the Forward P/E is also N/A, implying that traditional earnings-based valuation multiples cannot be applied to assess the expected earnings trajectory at this time. In the absence of a trailing P/E, the price-to-book ratio of 1.45 serves as a primary valuation metric, indicating that the market values the company at 1.45 times its book value, suggesting a premium over the net asset value which may reflect intangible assets or growth expectations not captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 0.46 and an EV/EBITDA of -13.61 offer different perspectives, with the low P/S ratio suggesting the company trades at a fraction of its sales, while the negative EV/EBITDA confirms the lack of earnings power required to generate positive enterprise value multiples. The stock's price volatility is contextualized by its 52-week range, with a high of $2.76 and a low of $0.58, and assuming a current price context relative to these bounds, the security trades within a wide band of historical volatility. The Beta is listed as N/A, which prevents a direct comparison of price volatility relative to the broader market, but the wide spread between the 52-week high and low indicates significant price instability common in small-cap biotechnology or retail stocks.
Growth & Income
The company experienced a revenue growth rate of -35.7% year-over-year and an earnings growth rate of -83.1% year-over-year, indicating that earnings are contracting at a much faster rate than revenue, which points to deteriorating profitability per unit sold or rising operational inefficiencies. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute profits to shareholders and instead retains earnings, though in this case, the retained earnings contribute to losses rather than growth capital. The negative earnings growth rate underscores that the business is currently in a contraction phase regarding profitability, while the significant revenue decline suggests a shrinking market share or demand in the OTC pharmaceutical distribution sector. The overall growth and income profile is characterized by double-digit contraction in earnings, a lack of dividend distribution, and a reliance on cash flow generation to sustain operations despite the absence of traditional growth indicators or income returns for shareholders.